TNF and Opportunistic infection: Initial observational studies, however, show that the risk of opportunistic infections is indeed higher in elderly patients compared to their younger counterparts when treated with monoclonal antibodies against tumor necrosis factor-alpha (anti-TNF), including infliximab, adalimumab, golimumab, and certolizumab [8,9,10].